Navigation Links
MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress
Date:12/2/2011

SAN DIEGO and MONTPELLIER, France, Dec. 2, 2011 /PRNewswire/ -- MedinCell, a leading developer of low-cost, controlled-release drug delivery technology, will be exploring partnerships for key companion and food animal markets with industry leaders at the Terrapinn World Animal Health Congress in Kansas City (December 6-8, 2011).

"MedinCell's biodegradable polymer technology offers exceptional control over the duration of drug release, thereby making small molecules—and even peptides—cost effective for the companion and food animal markets," said Dr. Alexandre Melin, Director of Animal Health for MedinCell. "Our platform's inherent flexibility enables us to design single-injection products that release drug molecules systemically over just a few days, or across multiple-months. With some APIs, we can achieve therapeutic plasma levels throughout an entire year," Dr. Melin (alexandre.melin@medincell.eu) continued.

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "MedinCell has experience formulating molecules for chemocastration, diabetes, pain control and parasitology. Our MedinGel™ technology brings a strong environmental benefit to animal health brands by reducing the required drug cargo, and therefore the amount of API cleared by the animals. This can also lead to a substantial reduction in product cost for animal health companies."

"MedinCell recognizes that the demand for protein production is increasing, and requires novel approaches to support the growing global population," commented Dr. Melin, who welcomes meeting requests at the World Animal Health Congress to discuss controlled-release strategies. "We look forward to designing novel products that improve product efficiency and animal treatment for the food animal industry," concluded Dr. Melin.

About MedinCell

MedinCell's patent-pending drug delivery technology, MedinGel, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration. With MedinGel, substantially less API cargo is required than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Information on the Terrapinn World Animal Health Congress is available online: http://www.terrapinn.com/2011/world-animal-health-congress/index.stm

 

 

CONTACT:  Chris Hoover, MedinCell Corporation, +1-858-216-4573, chris.hoover@medincell.com


'/>"/>
SOURCE MedinCell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
4. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
5. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
6. Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
7. Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
8. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
11. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is ... Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror ... Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
(Date:1/17/2017)... OAKLAND, CA (PRWEB) , ... January 17, 2017 , ... ... been named winners of the fourth Cradle to Cradle Product Design Challenge , ... the fourth in a series of six circular design challenges scheduled to run through ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
Breaking Medicine News(10 mins):